PL376754A1 - Związki heterocykliczne użyteczne jako aktywatory Nurr-1 - Google Patents

Związki heterocykliczne użyteczne jako aktywatory Nurr-1

Info

Publication number
PL376754A1
PL376754A1 PL376754A PL37675404A PL376754A1 PL 376754 A1 PL376754 A1 PL 376754A1 PL 376754 A PL376754 A PL 376754A PL 37675404 A PL37675404 A PL 37675404A PL 376754 A1 PL376754 A1 PL 376754A1
Authority
PL
Poland
Prior art keywords
nurr
activators
heterocyclic compounds
compounds useful
heterocyclic
Prior art date
Application number
PL376754A
Other languages
English (en)
Inventor
Samuel Hintermann
Bastian Hengerer
Boris Schmidt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL376754A1 publication Critical patent/PL376754A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL376754A 2003-02-14 2004-02-13 Związki heterocykliczne użyteczne jako aktywatory Nurr-1 PL376754A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0303503.7A GB0303503D0 (en) 2003-02-14 2003-02-14 Organic compounds

Publications (1)

Publication Number Publication Date
PL376754A1 true PL376754A1 (pl) 2006-01-09

Family

ID=9953078

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376754A PL376754A1 (pl) 2003-02-14 2004-02-13 Związki heterocykliczne użyteczne jako aktywatory Nurr-1

Country Status (14)

Country Link
US (1) US7432293B2 (pl)
EP (1) EP1597243A1 (pl)
JP (1) JP2006517564A (pl)
CN (2) CN101665469A (pl)
AR (1) AR043168A1 (pl)
AU (1) AU2004212151B2 (pl)
BR (1) BRPI0407479A (pl)
CA (1) CA2515847A1 (pl)
GB (1) GB0303503D0 (pl)
MX (1) MXPA05008584A (pl)
PE (1) PE20050193A1 (pl)
PL (1) PL376754A1 (pl)
TW (1) TW200502225A (pl)
WO (1) WO2004072050A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0409319B8 (pt) 2003-04-11 2021-05-25 Ptc Therapeutics Inc composto, composição farmacêutica, forma de dosagem unitária, e, uso de um composto
AU2005295727A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
CA2603402C (en) 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
RU2007139255A (ru) 2005-04-26 2009-06-10 Ньюросерч А/С (DK) Новые оксадиазольные производные и их медицинское применение
BRPI0710213A2 (pt) 2006-03-30 2011-04-12 Ptc Therapeutics Inc métodos para produzir uma quantidade efetiva de uma proteìna de transleitura funcional codificada por uma sequência de ácido nucleico que compreende uma mutação não-sentido e para tratar, controlar e/ou prevenir uma doença
FR2903108B1 (fr) * 2006-07-03 2008-08-29 Sanofi Aventis Sa Utilisation de derives d'imidazo[1,2-a] pyridine-2-carboxamides en therapeutique.
FR2903107B1 (fr) 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2903105A1 (fr) 2006-07-03 2008-01-04 Sanofi Aventis Sa Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
CA2662749C (en) 2006-09-08 2015-01-20 Ptc Therapeutics, Inc. Processes for the preparation of 1,2,4-oxadiazole benzoic acids
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
EP2068871B1 (en) 2006-09-25 2013-12-25 PTC Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
EP2076501B8 (en) * 2006-09-25 2019-11-13 PTC Therapeutics, Inc. Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
SI2073805T1 (sl) * 2006-10-12 2015-10-30 Ptc Therapeutics, Inc. Postopki za odmerjanje peroralno aktivnega 1,2,4-oksadiazola za zdravljenje supresije nesmiselnih mutacij
MX2010002258A (es) 2007-08-27 2010-04-22 Helicon Therapeutics Inc Compuestos terapeuticos de isoxazol.
PL2684873T3 (pl) 2008-06-09 2019-07-31 Ludwig-Maximilians-Universität München Leki do hamowania agregacji białek związanych z chorobami związanymi z agregacją białka i/lub chorobami neurodegeneracyjnymi
EP2300442A2 (en) * 2008-06-24 2011-03-30 Irm Llc Compounds and methods for modulating g protein-coupled receptors
FR2933609B1 (fr) 2008-07-10 2010-08-27 Fournier Lab Sa Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
WO2011009484A1 (en) * 2009-07-22 2011-01-27 Novartis Ag Arylpyrazoles and arylisoxazoles and their use as pkd modulators
FR2950053B1 (fr) 2009-09-11 2014-08-01 Fournier Lab Sa Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
FR2955110A1 (fr) * 2010-01-08 2011-07-15 Fournier Lab Sa Nouveaux derives de type pyrrolopyridine benzoique
CA2814628C (en) * 2010-10-14 2015-06-16 Daiichi Sankyo Company, Limited Acylbenzene derivative
EP3066083B1 (de) * 2013-11-05 2019-10-30 Bayer Animal Health GmbH Neue verbindungen zur bekämpfung von arthropoden
TWI695717B (zh) 2014-03-06 2020-06-11 美商 Ptc 治療公司 1,2,4-二唑苯甲酸之鹽及醫藥組合物
CN108348527A (zh) 2015-10-30 2018-07-31 Ptc医疗公司 用于治疗癫痫的方法
WO2018206778A1 (en) 2017-05-12 2018-11-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04295470A (ja) * 1991-03-22 1992-10-20 Wakamoto Pharmaceut Co Ltd モノアミンオキシダーゼ−b酵素阻害活性を有する1,2,4−オキサジアゾール誘導体及びその製造法
AU6526896A (en) * 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
DE19620041A1 (de) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
DE19816880A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JP2000080086A (ja) * 1998-07-01 2000-03-21 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
BR9911752A (pt) * 1998-07-01 2001-04-03 Takeda Chemical Industries Ltd Agente de regulagem da função do receptor relacionado com a retinóide, derivados de oxazol, de imidazol e de tiazol, composto, processo para regular uma função de receptor relacionado com a retinóide, e, uso de um derivado
ATE257827T1 (de) * 1999-07-21 2004-01-15 Hoffmann La Roche Triazolderivate
UA75871C2 (en) * 1999-08-19 2006-06-15 Nps Pharma Inc 1,2,4-oxadiazole derivatives and use thereof as antagonists at metabotropic glutamate receptors
RU2319701C2 (ru) * 2001-02-21 2008-03-20 Астразенека Аб ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I
US7223791B2 (en) * 2001-06-26 2007-05-29 Takeda Pharmaceutical Company Limited Function regulator for retinoid relative receptor

Also Published As

Publication number Publication date
US7432293B2 (en) 2008-10-07
BRPI0407479A (pt) 2006-02-07
JP2006517564A (ja) 2006-07-27
AU2004212151A1 (en) 2004-08-26
AR043168A1 (es) 2005-07-20
CN1747942A (zh) 2006-03-15
TW200502225A (en) 2005-01-16
CA2515847A1 (en) 2004-08-26
AU2004212151B2 (en) 2008-09-04
MXPA05008584A (es) 2005-11-04
CN100475795C (zh) 2009-04-08
WO2004072050A1 (en) 2004-08-26
EP1597243A1 (en) 2005-11-23
PE20050193A1 (es) 2005-04-11
CN101665469A (zh) 2010-03-10
GB0303503D0 (en) 2003-03-19
US20060089365A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
PL376754A1 (pl) Związki heterocykliczne użyteczne jako aktywatory Nurr-1
IL174375A0 (en) Novel heterocyclic compounds as hsp90-inhibitors
IL209082A0 (en) Fushed heterocyclic compounds
PL377087A1 (pl) Związki heterocykliczne
HK1091809A1 (en) 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators
EP1551801A4 (en) NOVEL GAMMA-LACTAMES AS INHIBITORS OF BETA-SECRETASE
SG131944A1 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
GB0304424D0 (en) Novel compounds
EP1596860A4 (en) NEW CONNECTIONS
EP1476425A4 (en) Heterocyclic Aryl Sulphonamidocyclic Compounds
EP1648885A4 (en) NEW CONNECTIONS
GB0305426D0 (en) Novel compounds
GB0302431D0 (en) Novel compounds
GB0302546D0 (en) Novel compounds
GB0304809D0 (en) Novel compounds
GB0403135D0 (en) Chiral compounds
ZA200509643B (en) 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators
EP1635834A4 (en) NEW COMPOUNDS
AU2003906640A0 (en) Heterocyclic compounds
GB0305165D0 (en) Novel compounds
GB0301955D0 (en) Novel compounds
GB0305163D0 (en) Novel compounds
GB0304811D0 (en) Novel compounds
GB0305290D0 (en) Novel compounds
GB0304803D0 (en) Novel compounds

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)